Rodolphe Barrangou

Rodolphe Barrangou
Name	Rodolphe Barrangou
Fields	Microbiology, Biotechnology, Genetics
Workplaces	North Carolina State University; DuPont; Intellia Therapeutics; Caribou Biosciences
Alma mater	AgroParisTech; Institut National Agronomique Paris-Grignon; North Carolina State University
Known for	CRISPR research; CRISPR–Cas immunity; genome editing applications

Rodolphe Barrangou is a microbiologist and biotechnologist notable for foundational work on adaptive immunity in prokaryotes and applied CRISPR–Cas technologies. He has bridged academic research and industrial development through positions at universities and biotech companies, contributing to gene editing, industrial microbiology, and intellectual property strategies. Barrangou's work influenced scientific fields, corporate partnerships, and regulatory discussions worldwide.

Early life and education

Barrangou studied at AgroParisTech and the Institut National Agronomique Paris-Grignon before pursuing graduate studies at North Carolina State University. During his doctoral training he engaged with laboratories associated with Dairy Science programs, interacting with researchers linked to USDA-funded initiatives and collaborations involving European Union research networks. His education placed him in contact with faculty connected to Institut Pasteur, INRAE, and industrial partners such as Danone, Nestlé, and Lactalis who have historical ties to dairy microbiology and fermentation research.

Research career and positions

Barrangou held academic posts at North Carolina State University and collaborated with researchers from University of California, Berkeley, Massachusetts Institute of Technology, and Harvard University. He has been employed in industry by DuPont and consulted for companies including Intellia Therapeutics, Caribou Biosciences, Editas Medicine, and CRISPR Therapeutics. His network spans laboratories at Broad Institute, J. Craig Venter Institute, and European Molecular Biology Laboratory; he has participated in consortia with National Institutes of Health, Wellcome Trust, and Horizon 2020-funded projects. Barrangou has lectured at venues such as Cold Spring Harbor Laboratory, Royal Society, and conferences organized by American Society for Microbiology and Biotechnology Innovation Organization.

Contributions to CRISPR–Cas systems

Barrangou's research provided empirical evidence for the adaptive immune function of clustered regularly interspaced short palindromic repeats in prokaryotes, integrating concepts from studies by Francisco Mojica, Emmanuelle Charpentier, and Jennifer Doudna. His work linked spacer acquisition, CRISPR array transcription, and interference mechanisms involving Cas9 and other Cas proteins, intersecting with structural insights from X-ray crystallography and cryo-electron microscopy studies at institutions like Max Planck Institute and Scripps Research. He contributed to demonstrations of phage resistance in industrial strains used by companies such as PhageTech and influenced applications developed by Synthetic Genomics and Ginkgo Bioworks. His studies informed patent disputes involving University of California and Broad Institute and shaped policy dialogues at United States Patent and Trademark Office and European Patent Office. Collaborations extended to microbial ecology groups at Woods Hole Oceanographic Institution and comparative genomics teams at European Bioinformatics Institute.

Commercialization and entrepreneurship

Barrangou participated in translating CRISPR discoveries into commercial products, advising startups including Intellia Therapeutics, Caribou Biosciences, Beam Therapeutics, and Mammoth Biosciences. He engaged with corporate research programs at DuPont to apply CRISPR to fermentation, strain engineering, and agricultural biotechnology with partners like Bayer, Syngenta, and Corteva. His entrepreneurial activities involved interactions with venture capital firms such as Sequoia Capital, Andreessen Horowitz, and Flagship Pioneering, and incubators including Y Combinator and IndieBio. Barrangou has been involved in licensing agreements, startup formation, and collaborations connecting academic technology transfer offices at North Carolina State University and commercial entities like Thermo Fisher Scientific and New England Biolabs.

Awards and honors

Barrangou received recognition from organizations including the National Academy of Inventors, American Academy of Microbiology, and industry awards presented by BIO and FierceBiotech. He has been invited to deliver named lectures at Cold Spring Harbor Laboratory, Royal Society, and Gordon Research Conferences. His honors relate to contributions acknowledged alongside peers such as Emmanuelle Charpentier, Jennifer Doudna, Feng Zhang, and George Church in contexts spanning Nobel Prize discussions, Breakthrough Prize nominations, and national science awards administered by entities like National Science Foundation and European Research Council.

Selected publications and patents

Barrangou is author or co-author on influential papers in journals including Science, Nature, Nature Biotechnology, Proceedings of the National Academy of Sciences, and Cell. Key publications address spacer acquisition, phage-host interactions, and genome editing applications, often cited alongside work from Francisco Mojica, Emmanuelle Charpentier, Jennifer Doudna, Feng Zhang, and George Church. His patent filings intersect with portfolios held by University of California, Broad Institute, Caribou Biosciences, and Editas Medicine and have been considered in proceedings at the United States Patent and Trademark Office and European Patent Office.

Category:Microbiologists Category:Biotechnologists